Analyst Reco. ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
68.05 ^USD	+3.29%		+1.19%	+23.41%

May. 10	ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance	MT
May. 10	Futures Rebound Pre-Bell Ahead of Earnings, Next Week's Inflation Reports; Asia, Europe Gain	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing	May. 03	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	Apr. 17	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,345,000, According to a Recent SEC Filing	Apr. 03	MT
Capital One Initiates ANI Pharmaceuticals at Overweight Rating	Mar. 15	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $83 From $73, Maintains Buy Rating	Mar. 04	MT
Truist Securities Raises Price Target on ANI Pharmaceuticals to $80 From $72, Maintains Buy Rating	Mar. 01	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $72 From $70, Maintains Buy Rating	Feb. 16	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $73 From $60, Maintains Buy Rating	23-08-22	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $62 From $59, Keeps Buy Rating	23-07-27	MT
Truist Adjusts ANI Pharmaceuticals' Price Target to $60 From $52, Keeps Buy Rating	23-07-21	MT
Guggenheim Adjusts Price Target on ANIP to $59 From $55, Maintains Buy Rating	23-05-09	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $52 From $50, Maintains Buy Rating	23-05-09	MT
Raymond James Adjusts Price Target on ANI Pharmaceuticals to $49 From $48, Maintains Outperform Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $60 From $53, Keeps Buy Rating	23-05-09	MT
Cantor Fitzgerald Adjusts ANI Pharmaceuticals Price Target to $42 From $40, Maintains Neutral Rating	23-05-08	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $53 From $50, Keeps Buy Rating	23-03-13	MT
Cosette Pharmaceuticals, Inc. Launches Betaine Anhydrous Powder, AB-rated to Cystadane (Betaine Anhydrous for Oral Solution)	23-03-02	CI
HC Wainwright Starts ANI Pharmaceuticals at Buy With $50 Price Target	22-09-07	MT
S&P Revises ANI Pharmaceuticals Outlook To Stable From Positive On Increased Expenses; 'B+' Ratings Affirmed	22-08-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Analyst Reco.

Filters